Immunotherapy for Infectious Diseases

174 Connick
39. Hurni MA, Bohlen L, Furrer H, et al. Complete regression of giant molluscum contagiosum
lesions in an HIV-infected patient following combined antiretroviral therapy with
saquinavir, zidovudine and lamivudine. AIDS 1997; 11:1784–1785.
40. Murphy M, Armstrong D, Sepkowitz KA, et al. Regression of AIDS related Kaposi’s sarcoma
following treatment with an HIV-1 protease inhibitor. AIDS 1997; 11:261–262.
41. Conant MA, Opp KM, Poretz D, et al. Reduction of Kaposi’s sarcoma lesions following
treatment of AIDS with ritonavir. AIDS 1997; 11:1300–1301.
42. Parra R, Leal M, Delgado J, et al. Regression of invasive AIDS-related Kaposi’s sarcoma
following antiretorviral therapy. Clin Infect Dis 1998; 26:218–219.
43. Uthayakumar S, Birthistle K, Dalton R, Hay PE. Cytomegalovirus retinitis after initiation
of highly active antiretroviral therapy. Lancet 1997; 350:588–589.
44. Jabs DA, Bolton SG, Dunn JP, et al. Discontinuing anticytomegalovirus therapy in patients
with immune reconstitution after combination antiretroviral therapy. Am J Ophthalmol
1998; 126:817–822.
45. Whitcup S, Fortin E, Lindblad A, et al. Discontinuation of anticytomegalovirus therapy in
patients with HIV infection and cytomegalovirus retinitis. JAMA 1999; 282:1633–1637.
46. Aberg JA, Yajko DM, Jacobson MA. Eradication of AIDS-related disseminated mycobacterium
avium complex infection after 12 months of antimycobacterial therapy combined
with highly active antiretroviral therapy. J Infect Dis 1998; 178:1446–1449.
47. Weverling GJ, Mocroft A, Ledergerber B, et al. Discontinuation of Pneumocystis carinii
pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection.
EuroSIDA Study Group. Lancet 1999; 353:1293–1298.
48. Schneider MME, Borleffs JCC, Stolk RP, et al. Discontinuation of Pneumocystis carinii
pneumonia prophylaxis in HIV-1 infected patients treated with highly active antiretroviral
therapy. Lancet 1999; 353:201–203.
49. Dworkin M, Hanson D, Jones J, et al. The risk for Pneumocystis carinii pneumonia (PCP)
and disseminated nontuberculous mycobacteriosis (dMb) after an antiretroviral therapy
(ART) associated increase in the CD4� T lymphocyte count. In: Abstracts of the 6th Conference
on Retroviruses and Opportunistic Infections, Chicago, IL, 1999 [Abstract No. 692].
50. Lopez JC, Pena JM, Miro JM, et al. Discontinuation of PCP prophylaxis (PRO) is safe in
HIV-infected patients (PTS) with immunological recovery with HAART. Preliminary
results of an open randomized and multicenter clinical trial (GESIDA 04/98). In: Abstracts
of the 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, 1999
[Abstract No. LB7].
51. Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against
Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral
therapy. Swiss Cohort Study. N Engl J Med 1999; 340:1301–1306.
52. Currier JS, Williams PL, Koletar SL, et al. Discontinuation of Mycobacterium avium complex
prophylaxis in patients with antiretroviral therapy-induced increases in CD4� cell
count. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000;
133:493–503.
53. El-Sadr WM, Burman WJ, Grant LB, et al. Discontinuation of prophylaxis for Mycobacterium
avium complex disease in HIV-infected patients who have a response to antiretroviral
therapy. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl
J Med 2000; 243:1085–1092.
54. Furrer H, Telenti A, Rossi M, Ledergerber B. Discontinuing or withholding primary prophylaxis
against Mycobacterium avium in patients on successful antiretroviral combination
therapy. The Swiss HIV Cohort Study. AIDS 2000; 14:1409–1412.
55. Anonymous. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections
in persons infected with human immunodeficiency virus. MMWR 1999; 48:1–59.
56. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after highly active
antiretroviral therapy. Lancet 1997; 349:1443–1445.